Document is current
Any future updates will be listed below
-
Authors
Melssen, Marit M.
Petroni, Gina R.
Chianese-Bullock, Kimberly A.
Wages, Nolan A.
Grosh, William W.
Varhegyi, Nikole
Smolkin, Mark E.
Smith, Kelly T.
Galeassi, Nadejda V.
Deacon, Donna H.
Gaughan, Elizabeth M.
Slingluff, Craig L. https://orcid.org/0000-0002-6664-4373
-
Funding
Funding for this research was provided by:
National Institutes of Health (NCI RO1 CA057653)
National Cancer Institute (5K25CA181638)
Alice and Bill Goodwin (gift)
Commonwealth Foundation for Cancer Research (Gift)
Cancer Research Institute (Clinical and Laboratory Integration Project)
Rebecca Clary Harris Memorial Fellowship (not applicable)
National Cancer Institute (P30 CA044579)
- License Information
-
More Information
Article History
Received: 18 January 2019
Accepted: 17 May 2019
First Online: 27 June 2019
Ethics approval and consent to participate
: The clinical trial Mel58 was performed with IRB (#15781) and FDA approval and is registered withon April 25, 2012 (NCT01585350). Patients provided written informed consent to participate.
: Not applicable.
: C.L. Slingluff Jr. reports receiving commercial research grants from Merck, GlaxoSmithKline, 3 M, and Celldex; has ownership interest (including patents) in several of the peptides used in the 12MP vaccine with UVA Licensing and Ventures Group; and is a consultant/advisory board member for Immatics, Curevac, and Polynoma. No potential conflicts of interest were disclosed by the other authors.
